Page URL:

Selected biotech news

26 April 1999
By BioNews
Appeared in BioNews 5

Shield Diagnostics has signed an exclusive deal with Gemini Holdings which will allow them to develop Gemini's DNA based test for a gene that causes a predisposition to brittle-bone disease. Shield Diagnostics said the test could have other applications. The colourful banker, Mungo Parks, who masterminded Nomura International's attempt to 'own' the emerging pharmaceutical sector in the UK, has left the Japanese investment bank two years after he joined the firm. He used Nomura's resources to take large stakes in a number of biotechnology companies such as Xenova, Phytopharm and PPL, the company behind the cloning experiments that led to Dolly the sheep. Investments built up by Nomura in this sector total more than £50 million.

Nomura's colourful biotech king quits
The Times |  24 April 1999
Shield's DNA deal
The Independent |  20 April 1999
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.